Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

British Journal of Cancer

Volumn 114, Issue 8, 2016, Pages 872-880

  Loskog, Angelica ^a   Maleka, Aglaia ^a,b   Mangsbo, Sara ^a   Svensson, Emma ^a   Lundberg, Christina ^b   Nilsson, Anders ^b   Krause, Johan ^b   Agnarsdóttir, Margret ^a,b   Sundin, Anders ^a,b   Ahlström, Hakan ^a,b   Tötterman, Thomas H ^a   Ullenhag, Gustav ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AdCD40L; adenovirus; CD40L; immunotherapy; melanoma

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 8; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 8; TRANSCRIPTION FACTOR FOXP3; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOSTIMULATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SHIVERING; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VIRAL GENE THERAPY; VITILIGO; VOMITING; ADENOVIRIDAE; GENE THERAPY; GENE VECTOR; GENETICS; MELANOMA; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CD40 LIGAND; CYCLOPHOSPHAMIDE; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MELANOMA; MIDDLE AGED; YOUNG ADULT;

EID: 84962106627     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.42     Document Type: Article

References (17)

1. Bernatchez C, Radvanyi LG, Hwu P. (2012). Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 39: 215-226
2. Gehan EA. (1961). The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353
3. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. (1998). A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514
4. Hodi FS, O Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723
5. Hwang JP, Lim I, Na, Cho EH, Kim BI, Choi CW, Lim SM. (2014). Prognostic value of SUVmax measured by fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with gallbladder cancer. Nucl Med Mol Imaging 48: 114-120
6. Loskog A, Totterman TH. (2007). CD40L -a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7: 23-28
7. Lutzky J. (2010). New therapeutic options in the medical management of advanced melanoma. Semin Cutan Med Surg 29: 249-257
8. Malmstrom PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gardmark T, Totterman TH. (2010). AdCD40L immunogene therapy for bladder carcinoma-the first phase I/IIa trial. Clin Cancer Res 16: 3279-3287
9. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. (2006). Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol 3: 668-681
10. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714
11. Sullivan RJ, Lorusso PM, Flaherty KT. (2013). The intersection of immunedirected and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 19: 5283-5291
12. Tong AW, Stone MJ. (2003). Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10: 1-13
13. Ugurel S, Rappl G, Tilgen W, Reinhold U. (2001). Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577-583
14. van den Oord JJ, Maes A, Stas M, Nuyts J, Battocchio S, Kasran A, Garmyn M, De Wever I, De Wolf-Peeters C. (1996). CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 149: 1953-1961
15. Weber J. (2007). Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872
16. Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog AS, Totterman TH, von Euler H. (2013). Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother 36: 350-358
17. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. (1999). Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782